Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Colorcon
Boehringer Ingelheim
McKinsey
McKesson

Last Updated: September 27, 2022

Details for Patent: 6,787,531


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 6,787,531
Title: Pharmaceutical composition for use as a contraceptive
Abstract:A pharmaceutical composition comprises, as a first active agent, 6.beta.,7.beta.; 15.beta.,16.beta.-dimethylene-3-oxo-17.alpha.-pregn-4-ene-21,17-carbolacto ne (drospirenone) in an amount corresponding to a daily dosage, on administration of the composition, of from about 2 mg to about 4 mg, and, as a second active agent, 17.alpha.-ethinylestradiol (ethinylestradiol) in an amount corresponding to a daily dosage of from about 0.01 mg to about 0.05 mg, together with one or more pharmaceutically acceptable carriers or excipients. In a specific embodiment, the composition consists of a number of separately packaged and individually removable daily dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 consecutive days, wherein said daily dosage units comprises the combination of drospirenone and ethinylestradiol. The composition may further comprise 7 or less daily dosage units containing no active agent or containing ethinylestradiol alone.
Inventor(s): Hilman; Juergen (Berlin, DE), Heil; Wolfgang (Berlin, DE), Lipp; Ralph (Berlin, DE), Heithecker; Renate (Berlin, DE), Huempel; Michael (Berlin, DE), Tack; Johannes W. (Berlin, DE)
Assignee: Schering AG (Berlin, DE)
Application Number:09/654,227
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,787,531
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Device;

Drugs Protected by US Patent 6,787,531

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,787,531

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 025443 See Plans and Pricing
Argentina 043470 See Plans and Pricing
Austria 254464 See Plans and Pricing
Austria 420648 See Plans and Pricing
Austria 429231 See Plans and Pricing
Australia 2005202046 See Plans and Pricing
Australia 2009200247 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Baxter
Mallinckrodt
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.